GDNF gene delivery via the p75(NTR) receptor rescues injured motor neurons.
The retrograde axonal transport mechanism of motor neurons has been exploited to deliver the gene encoding Glial cell line-derived neurotrophic factor (GDNF) into the central nervous system to provide trophic support following injury. A nonviral gene delivery system, consisting of a monoclonal antibody (MC192) that binds the neurotrophic receptor, p75(NTR), coupled to poly-L-lysine, was constructed and used to deliver the gene via a receptor-mediated mechanism. The MC192-poly-l-lysine/pGDNF complex was injected into the hind limb of newborn rats to allow gene expression within motor neurons prior to sciatic nerve transection. In adult rats, the gene delivery complex was administrated in gel foam placed on a transected hypoglossal nerve. We show that the delivered construct is internalized following binding to p75(NTR) and is transported into the brain and spinal cord, bypassing the blood-brain barrier. The presence of the GDNF transgene and its transcript could be detected for up to 8 weeks in spinal cord and brain stem. Expression of the GDNF protein rescued 38% of the targeted motor neurons 1 week postinjury in newborn rats while the survival rate in control group was below 12%. In adult rats, neuronal death induced by axotomy was almost completely reversed by the introduction of the transgene (95 +/- 3%). Thus, the significant functional outcomes of this novel gene delivery system are demonstrated both in postnatal and adult motor neurons.
Barati
Shahram
S
Department of Human Physiology and Centre for Neuroscience, Flinders Medical Research Institute, Flinders University of South Australia, GPO Box 2100, Adelaide 5001, Australia. Shahram.Barati@flinders.edu.au
Hurtado
Plinio R
PR
Zhang
Shu H
SH
Tinsley
Rogan
R
Ferguson
Ian A
IA
Rush
Robert A
RA
D000818:Animals; D000831:Animals, Newborn; D002452:Cell Count / Q000379:methods; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000378:metabolism / Q000627:therapeutic use*; D005909:Glioblastoma; D008297:Male; D016472:Motor Neuron Disease / Q000473:pathology* / Q000628:therapy*; D009046:Motor Neurons / Q000187:drug effects* / Q000502:physiology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020800:Receptor, Nerve Growth Factor / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods
D051100:Glial Cell Line-Derived Neurotrophic Factor; D012333:RNA, Messenger; D020800:Receptor, Nerve Growth Factor